Ecteinascidin 729

Drug Profile

Ecteinascidin 729

Alternative Names: ET 729; NSC 638718

Latest Information Update: 21 Jan 2017

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 20 Jan 2017 Discontinued - Preclinical for Cancer in Spain (Parenteral)
  • 20 Jan 2017 Discontinued - Preclinical for Cancer in USA (Parenteral)
  • 08 Oct 1999 ET 729 is now called ecteinascidin 729
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top